Bryan Garnier - ONWARD OPPORTUNITIES LIMITED (ONWD) ONWARD Medical: ARC-EX recognised as one of TIMEs Best Inventions of 2024

Report

Bryan Garnier

Maria Vara

ONWARD Medical: ARC-EX recognised as one of TIME's Best Inventions of 2024

ONWARD Medical's investigational ARC-EX System was named one of TIME's Best Inventions of 2024, spotlighting its potential to improve life for SCI. Recognised for originality, efficacy, ambition, and impact, the ARC-EX System enables SCI patients to regain hand and arm function, as evidenced by the

31/10/2024 1 EN

Underlying

ONWARD OPPORTUNITIES LIMITED

See profile

GG00BMZR1514 London Stock Exchange Guernsey

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Maria Vara

Other Reports on these Companies

Bryan Garnier

ONWARD Medical: successful EUR50m upsized raise with Ottobock as cornerstone investor

ONWARD Medical successfully secured a capital raise of EUR50m in total gross proceeds through an upsized bookbuild offering via a private placement. Ottobock contributed EUR22.5m as a strategic cornerstone investor, with the potential for synergistic value creation in both the near and long term. T

October 24, 2024 October 24, 2024 1 EN

Bryan Garnier

ONWARD Medical: bolsters leadership ahead of ARC-EX launch

This morning, ONWARD Medical announced that Rob ten Hoedt, former EVP at Medtronic and Chairman of MedTech Europe, will join its Board of Directors and take over as Chairman by YE, following the planned retirement of Jan Ohrstrom after 8 years of service. Ten Hoedt's experience at Medtronic and lea

October 21, 2024 October 21, 2024 1 EN

ATOSS Software initiation: the writing is on the wall

We initiate coverage of ATOSS Software, a German workforce management vendor (not to be confused with unrelated Atos), which despite its high fundamental quality, is facing significant risks of slowing growth, difficulties to expand beyond DACH, technological disruption, insufficient reinvestment o

15h / 46m 15h / 46m 1 EN

Maria Vara

Maria Vara

Median Technologies: KOL webinar on eyonis LCS on 7th Nov — save the date!

With relevant clinical validation catalysts met, we view Median's KOL webinar on eyonis LCS a unique occasion to deep dive into the outstanding data provided so far as the path to commercialisation shortens. While we previously had visibility on the top-line REALITY study — meeting all primary and

18h / 12m 18h / 12m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONWARD Medical: ARC-EX recognised as one of TIME's Best Inventions of 2024

ONWARD Medical: successful EUR50m upsized raise with Ottobock as cornerstone investor

ONWARD Medical: bolsters leadership ahead of ARC-EX launch

ATOSS Software initiation: the writing is on the wall

Median Technologies: KOL webinar on eyonis LCS on 7th Nov — save the date!

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe